名称 | TIGIT/PVRIG Dual Effector Reporter Cell |
型号 | CBP74167 |
报价 | ![]() |
特点 | TIGIT/PVRIG Dual Effector Reporter Cell |
产品搜索
相关文章
联系我们
电话:86-25-86880024
号码:86-25-86880024
手机:18066071954
地址:南京市雨花区长虹路222号
Email: zhangxiangwen@cobioer.com
产品展示 / PRODUCTS

- 详细内容
CBP74167 | |
I. Background | |
TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory T cells. Interaction with the poliovirus receptor (PVR; CD155) on antigen presenting cells, such as dendritic cells, recruits Src homology (SH) domain-containing protein tyrosine phosphatase SHP1 and SHP2 or the inositol phosphatase SHIP1 and SHIP2 to the TIGIT ITIM domain. This increases IL-10 release and suppresses NF-kB and NFAT T cell receptor (TCR) signaling, which blocks T cell proliferation and cytokine production. It serves as a competitive inhibitor of CD226, a co-stimulatory receptor for CD155. TIGIT targeting antibodies that block this T cell-intrinsic inhibitory effects have shown enhanced anti-tumor and anti-viral functions in preclinical studies. PVRIG (CD112R) is an regulatory protein expressed on T-cells which inhibits immune activation when binding to its counterpart on APCs, PVRL2 (CD112, Nectin-2). Since both PVRL2 and PVR can activate DNAM-1 (CD226), PVRIG works synergistically with and separately from TIGIT. PVRL2 is overexpressed in a variety of tumor types, including breast and ovarian cancers, suggesting that its interaction with PVRIG is a major mechanism of immune suppression in those diseases. | |
II. Introduction | |
Expressed gene: | TIGIT/PVRIG |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+800 ug/ml hygromycin+10ug/ml blasticidin |
Mycoplasma Testing: | Negative |
Storage: | Liquid nitrogen |
Application(s): | Functional(Report Gene) Assay |
III. Representative Data | |
Figure 1. Recombinant TIGIT/PVRIG Dual Effector Reporter Cell constitutively expressing TIGIT. Figure 2. Recombinant TIGIT/PVRIG Dual Effector Reporter Cell constitutively expressing PVRIG. | |
Figure 3. Dose Response of Blocking Antibodies in TIGIT/PVRIG Dual Effector Reporter Cells(C45) With CD112/CD155 Dual aAPC Cells. | |